Masimo (NASDAQ:MASI) Issues FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 5.100-5.400 for the period, compared to the consensus EPS estimate of 4.690. The company issued revenue guidance of -.

Masimo Trading Down 5.7 %

MASI stock opened at $175.61 on Friday. The company’s 50-day simple moving average is $174.88 and its 200-day simple moving average is $155.41. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo has a 52-week low of $101.61 and a 52-week high of $194.88. The firm has a market cap of $9.47 billion, a P/E ratio of 121.11 and a beta of 1.02.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. As a group, equities analysts forecast that Masimo will post 4.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MASI. Stifel Nicolaus restated a “buy” rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Wells Fargo & Company upped their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler upped their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Raymond James increased their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.